MEENAKSHI HEGDE to Antibodies, Monoclonal, Humanized
This is a "connection" page, showing publications MEENAKSHI HEGDE has written about Antibodies, Monoclonal, Humanized.
Connection Strength
0.175
-
A Phase I, Open-Label, Dose Escalation Study of Enoblituzumab in Children and Young Adults with B7-H3-Expressing Relapsed or Refractory Solid Tumors. Cancer Res Commun. 2025 Sep 01; 5(9):1574-1583.
Score: 0.175